BPC-157 and TB-500 stack (UK research notes): rationale, dosing conventions, caveats

The pairing of BPC-157 with thymosin beta-4 (TB-500) shows up constantly in UK research inboxes. The rationale rests on complementary preclinical mechanisms: BPC-157 accelerates angiogenesis and tenocyte activity locally; TB-500 promotes actin sequestration, cell migration, and myocardial/endothelial repair in rodent injury models (Malinda et al., 1999; Sosne et al., 2010).

Dosing conventions in the animal literature typically use BPC-157 at 10 µg/kg and TB-500 at ~2 mg twice weekly (rodent-equivalent scaling). Neither has completed randomised human trials for tendinopathy or soft-tissue injury. See the peptide stacking guide for full protocol references and the BPC-157 vs TB-500 comparison for mechanistic differences.

Neither peptide has MHRA marketing authorisation. Both are prohibited under WADA S0. UK supply is for laboratory research only.